We are live on
!
Find out more
AA
ALPS Advisors Portfolio holdings
AUM
$21.3B
1-Year Est. Return
21.71%
This Fund
S&P 500
This Quarter
Est. Return
+0.5%
1 Year Est. Return
+21.71%
3 Year Est. Return
+77.63%
5 Year Est. Return
+121.1%
10 Year Est. Return
+198.29%
AUM
$13.5B
AUM Growth
-$613M
(-4.3%)
Cap. Flow
-$587M
Cap. Flow
% of AUM
-4.35%
Top 10 Holdings %
Top 10 Hldgs %
48.28%
Holding
914
New
36
Increased
203
Reduced
624
Closed
38
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MPLX
MPLX
|
+$30.1M |
| 2 |
Energy Transfer Partners
ET
|
+$24.7M |
| 3 |
Franklin FTSE Japan ETF
FLJP
|
+$11.8M |
| 4 |
Wells Fargo
WFC
|
+$9.66M |
| 5 |
Alkermes
ALKS
|
+$8.97M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MMP
Magellan Midstream Partners, L.P.
MMP
|
+$49.8M |
| 2 |
Enterprise Products Partners
EPD
|
+$49.1M |
| 3 |
Western Midstream Partners
WES
|
+$44.8M |
| 4 |
BPL
Buckeye Partners, L.P.
BPL
|
+$42.5M |
| 5 |
EQM
EQM Midstream Partners, LP
EQM
|
+$28.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Energy | 65.41% |
| 2 | Financials | 7.05% |
| 3 | Healthcare | 3.6% |
| 4 | Consumer Discretionary | 3.1% |
| 5 | Technology | 2.81% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALBO
376
DELISTED
Albireo Pharma Inc
ALBO
| $812K | 0.01% |
25,190
-3,722
| -13% | -$124K |
|
377
Zimmer Biomet
ZBH
$17.7B
| $798K | 0.01% |
6,979
+108
| +2% | +$12.6K |
|
378
Macerich
MAC
$7.32B
| $794K | 0.01% |
23,701
+3,056
| +15% | +$120K |
|
|
PDLI
379
DELISTED
PDL BioPharma, Inc.
PDLI
| $793K | 0.01% |
252,511
-100,077
| -28% | -$325K |
|
380
Tanger
SKT
$4.82B
| $792K | 0.01% |
48,876
+8,290
| +20% | +$149K |
|
381
AC Immune
ACIU
$227M
| $785K | 0.01% |
141,372
-21,335
| -13% | -$109K |
|
|
VEDL
382
DELISTED
Vedanta Limited American Depostary Shares (Each representing four equity shares)
VEDL
| $785K | 0.01% |
77,193
-1,355
| -2% | -$13.3K |
|
|
SEMG
383
DELISTED
SEMGROUP CORPORATION
SEMG
| $783K | 0.01% |
65,270
-8,835
| -12% | -$117K |
|
|
HAPN
384
Happen Inc
HAPN
$2.08B
| $782K | 0.01% |
47,691
+11,367
| +31% | +$179K |
|
385
Avista
AVA
$3.47B
| $780K | 0.01% |
17,487
-255
| -1% | -$10.9K |
|
386
Gen Digital
GEN
$15.6B
| $779K | 0.01% |
35,820
+8,051
| +29% | +$173K |
|
387
3D Systems Corp
DDD
$420M
| $778K | 0.01% |
85,549
+37,562
| +78% | +$356K |
|
|
ACHN
388
DELISTED
Achillion Pharmaceuticals
ACHN
| $778K | 0.01% |
290,360
-44,450
| -13% | -$131K |
|
|
FARO
389
DELISTED
Faro Technologies
FARO
| $776K | 0.01% |
14,751
+3,092
| +27% | +$156K |
|
390
Genuine Parts
GPC
$17.1B
| $773K | 0.01% |
7,467
| – | – |
|
|
ACOR
391
DELISTED
Acorda Therapeutics
ACOR
| $773K | 0.01% |
840
-119
| -12% | -$146K |
|
392
Enovis
ENOV
$1.56B
| $771K | 0.01% |
15,978
-123,869
| -89% | -$5.96M |
|
|
PHAS
393
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
| $771K | 0.01% |
+58,775
| New | +$720K |
|
|
PFPT
394
DELISTED
Proofpoint, Inc.
PFPT
| $770K | 0.01% |
6,407
+1,783
| +39% | +$210K |
|
395
United Rentals
URI
$71.1B
| $761K | 0.01% |
5,734
| – | – |
|
396
Protolabs
PRLB
$1.86B
| $759K | 0.01% |
6,545
+1,610
| +33% | +$173K |
|
397
Idexx Laboratories
IDXX
$42.9B
| $757K | 0.01% |
2,750
-828
| -23% | -$204K |
|
398
LendingTree
TREE
$544M
| $756K | 0.01% |
1,801
+87
| +5% | +$33.3K |
|
|
DISCK
399
DELISTED
Discovery, Inc. Series C Common Stock
DISCK
| $755K | 0.01% |
26,525
-1,327
| -5% | -$36K |
|
400
Marker Therapeutics
MRKR
$20.3M
| $754K | 0.01% |
+9,515
| New | +$565K |
|
Similar funds
PAG
MMH
IC
DSA
VARA
SC
CB
ALPS Advisors's Q2 2019 Portfolio in Review
As of Q2 2019, ALPS Advisors held 914 positions worth $13.5B, down 4.3% from $14.1B the previous quarter. Its ten largest holdings account for 48% of the portfolio.
ALPS Advisors withdrew a net $587M in Q2 2019, closing 38 positions and reducing 624 holdings. Its most notable exit was Lakefront Biotherapeutics American Depositary Shares, an estimated $10.3M position sold in full.
By sector, the portfolio is most concentrated in Energy at 65% of assets, down from 66% a quarter earlier, followed by Financials and Healthcare.
Against the trend, ALPS Advisors opened a new position in Franklin FTSE Japan ETF worth $11.8M.
- ALPS Advisors's largest Q2 2019 buy was Franklin FTSE Japan ETF: 491,070 shares worth $11.8M.
- ALPS Advisors added most to MPLX in Q2 2019, an estimated $30.1M increase.
- ALPS Advisors's biggest Q2 2019 reduction was Magellan Midstream Partners, L.P., cutting an estimated $49.8M.
- ALPS Advisors fully exited Lakefront Biotherapeutics American Depositary Shares in Q2 2019, selling an estimated $10.3M.
- ALPS Advisors's ten largest holdings make up 48% of its $13.5B portfolio in Q2 2019.
- ALPS Advisors opened 36 new positions and closed 38 in Q2 2019.
- ALPS Advisors's portfolio value fell 4.3% quarter-over-quarter to $13.5B.
Based on ALPS Advisors's 13F filing for Q2 2019, filed 7 Aug 2019.